

1 **Metabolic traits and the risk of head and neck cancer:**
2 **a systematic review and meta-analysis**

3
4 Alexander J Gormley ^{1,2*}, Charlotte Richards ^{3*}, Francesca Spiga ^{4,5}, Alex Whitmarsh ⁴, Emily
5 Gray ², Jo Hooper ⁶, Barry G Main ^{1,2}, Emma E Vincent ^{4,5,7}, Rebecca C Richmond ^{4,5}, Julian PT
6 Higgins ^{4,5}, Mark Gormley ^{1,2,4,5}

7
8 ¹ Bristol Dental School, Faculty of Health Sciences, University of Bristol

9 ² Bristol Dental Hospital, University Hospitals Bristol and Weston NHS Foundation Trust

10 ³ School of Dentistry, Cardiff University

11 ⁴ Population Health Sciences, Bristol Medical School, University of Bristol

12 ⁵ MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School,
13 University of Bristol

14 ⁶ Library and information services, University Hospitals Bristol and Weston NHS Foundation
15 Trust

16 ⁷ School of Cellular and Molecular Medicine, Bristol Medical School, University of Bristol

17 * Joint first authors

18

19 Corresponding author

20 Email: mark.gormley@bristol.ac.uk

21

22

23

24 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

25 **Abstract**

26

27 **Introduction**

28

29 The overall incidence of head and neck cancer (HNC) continues to rise, despite a decline in
30 smoking rates, particularly within developed countries. Obesity and related metabolic traits
31 have been attributed to a growth in cancer rate, so further exploration of these risk factors
32 is warranted in HNC. A comprehensive systematic review and meta-analysis was conducted
33 in order to obtain the most precise observational estimates between metabolic trait
34 exposures and risk of HNC.

35

36 **Methods**

37

38 A search strategy was developed with an information and content specialists. Multiple
39 databases including Cochrane Library, OVID SP versions of Medline, EMBASE, pre-prints and
40 the grey literature were searched. The primary outcome for included studies was incident
41 HNC and exposures included obesity defined by body mass index (BMI), type 2 diabetes,
42 dyslipidaemia, and hypertension, using pre-specified definitions. A combined risk effect
43 across studies was calculated using both fixed and random-effects meta-analysis.
44 Heterogeneity was assessed between studies using the Cochran's Q and I^2 statistical tests.
45 The ROBINS-E preliminary tool was used to assess the bias in each included result.

46

47 **Results**

48

49 The search generated 7,316 abstracts, of these 197 full text articles were assessed for
50 eligibility and 36 were included for full qualitative and quantitative synthesis. In the analysis
51 of 5 studies investigating the association between obesity and incidence of HNC, there was
52 an overall RR of 1.06 (95%CI (0.76, 1.49), P heterogeneity <0.024 , $I^2= 73.2\%$) using a
53 random-effects model. 6 studies reported on the association between type 2 diabetes and
54 incidence of HNC, with an overall RR of 1.13 (95%CI (0.95, 1.34), P heterogeneity= <0.0001 ,
55 $I^2= 80.0\%$) using a random-effects model. An increased risk of hypertension was consistent
56 across HNC subsites, with the strongest association found in the larynx (RR= 1.17, 95%CI

57 (1.10, 1.25), *P* heterogeneity= 0.186, $I^2= 37.7\%$). For dyslipidaemia, only 2 studies were
58 available for meta-analysis in the laryngeal subsite, with some evidence of an increased risk
59 association of both low high-density lipoprotein (RR= 1.12, 95%CI (1.07, 1.18), *P*
60 heterogeneity= 0.103, $I^2= 62.5\%$) and high triglyceride levels (RR= 1.10, 95%CI (1.05, 1.15), *P*
61 heterogeneity= 0.319, $I^2= 0.0\%$) using random-effects models. Over 80% of studies were
62 judged to be at Very High or High risk of bias using the ROBINS-E tool.

64 **Conclusion**

65
66 Despite individual studies suggesting an association between BMI and HNC, limited effect
67 was demonstrated in this meta-analysis. There was evidence of an association between
68 hypertension and dyslipidaemia on incident HNC, however caution is required due to the
69 high levels of heterogeneity recorded in these studies. Observational associations are
70 susceptible to confounding, bias and reverse causality so these results must be interpreted
71 with caution. Future work should include meta-analysing studies separately by geographic
72 region, as this appears to be a clear source of heterogeneity.

73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88

89 Introduction

90

91 Despite the significant reduction in smoking ¹, particularly in developed countries, the
92 overall incidence of head and neck cancer (HNC) continues to rise ^{2,3}. Given this potentially
93 changing aetiology ⁴, further exploration of other risk factors is warranted to enhance
94 prevention strategies. According to the World Health Organization (WHO), at least 40% of
95 all cancer cases may be preventable, with smoking, alcohol consumption and obesity
96 identified as three of the most important modifiable lifestyle factors ⁵. The growth in cancer
97 attributable to metabolic risk is increasing, with a global attributable fraction due to high
98 body mass index (BMI) at around 3.6%, equating to almost half a million new cases each
99 year ^{6,7}. Public health strategies have been unsuccessful in addressing the current obesity
100 epidemic at the population level, which could also result in more overall cancer cases in the
101 years to come ⁸. It has been projected that obesity could even supersede smoking as the
102 primary driver of cancer in the coming decades ⁵.

103

104 People living with obesity and associated metabolic traits have an increased risk of
105 developing cancer ⁵, but the epidemiological evidence surrounding HNC is not conclusive
106 ^{9,10}. In the largest pooled analysis, obesity defined by higher BMI was associated with a
107 protective effect for HNC in current smokers (hazard ratio (HR)= 0.76, 95%CI (0.71, 0.82),
108 $p < 0.0001$, per 5 kg/m²) and conversely, a higher risk in never smokers (HR= 1.15, 95%CI
109 (1.06, 1.24) per 5 kg/m², $p < 0.001$) ¹¹. More recent cohort studies have failed to show a clear
110 association between BMI and HNC ¹²⁻¹⁶. Similarly, a meta-analysis of observational studies
111 investigating type 2 diabetes with oral and oropharyngeal subsites found an increased risk
112 ratio (RR) of 1.15, 95%CI (1.02, 1.29) ¹⁷. This finding has been supported by more recent
113 independent cohorts ^{12,18-20}. Lastly, hypertension (raised systolic blood pressure (SBP) or
114 diastolic blood pressure (DBP)), has been correlated with head and neck cancer risk across
115 multiple studies ¹⁹⁻²³. There are a number of proposed mechanisms linking these metabolic
116 traits and cancer, with none specifically linked to HNC. In short, hyperglycaemia may
117 provide a substrate for tumour growth or lead to direct DNA mutation. Insulin itself is a
118 potent growth factor, thought to promote proliferation and carcinogenesis both directly and
119 indirectly through insulin like growth factor-1 (IGF-1) ²⁴⁻²⁶. Insulin resistance can lead to a
120 chronic proinflammatory environment and the formation of macrophages which produce

121 mutagenic agents and reactive oxygen species leading to DNA damage ²⁷. Any underlying
122 mechanism between hypertension and cancer risk remains unknown ²³. Lipids are an
123 essential component of the cell wall and so increased cellular uptake of cholesterol has
124 been seen in many cancers, while other malignancies have demonstrated lipid metabolism
125 reprogramming which can help promote a cancer cell phenotype including proliferation,
126 differentiation and metastasis ²⁸.

127
128 We aimed to conduct the largest, most comprehensive systematic review and meta-analysis
129 to date, in order to obtain the most precise observational association between metabolic
130 traits and risk of HNC. If available, results were stratified by subsite (i.e., oral cavity,
131 oropharynx, hypopharynx, and larynx), with pre-defined subgroup analyses performed to
132 enhance interpretation, and additional sensitivity analysis to improve certainty in the
133 results.

134

135 **Methods**

136

137 *Research Question*

138 ‘Do metabolic traits affect the risk of developing head and neck cancer?’

139

140 *Eligibility criteria*

141 **Population-** participants over 18 years old, of either sex, from any country or ethnic
142 background.

143 **Exposures-** 1) obesity, 2) type 2 diabetes, 3) hypertension and 4) dyslipidaemia as defined in
144 the study protocol below. These will be collectively described as metabolic traits.

145 **Comparison-** participants who have not been diagnosed with a metabolic trait(s).

146 **Outcome-** incident head and neck squamous cell carcinoma (HNC).

147

148 *Study Selection*

149 We focused on prospective observational studies reporting the risk of metabolic traits on
150 incident HNC. This was to ensure a direct temporal relationship between the exposure and
151 onset of head and neck cancer. Eligibility criteria are detailed in **Table 1**.

152

153 *Data sources and search strategy*

154 A systematic search strategy (**Supplementary Table 1**) was formulated by clinicians,
155 scientific researchers and a specialist librarian for Head & Neck Surgery and Medicine.
156 Medical Subject Headings (MeSH) and keywords were iteratively combined with the
157 Boolean operators AND, OR and NOT. Multiple databases were searched from January 1966
158 – November 2021, including OVID SP versions of Medline and EMBASE, using the formulated
159 search strategy (**Supplementary Table 1**). Pre-print servers *medRxiv* (since June 2019) and
160 *BioRxiv* (since November 2013) were also searched. In addition, the following electronic
161 bibliographic databases were comprehensively searched: EThOS, Google Scholar, Open Grey
162 and ClinicalTrials.gov, to identify articles from the grey literature and conference
163 proceedings using a modified search strategy (**Supplementary Table 2**). References
164 extracted from the full-length articles were reviewed to identify other publications of
165 interest. Duplicate articles were removed using Covidence (*Covidence systematic review*
166 *software*, Veritas Health Innovation, Melbourne, Australia) ²⁹.

167

168 **Table 1. Study selection criteria**

169

Inclusion criteria	Exclusion criteria
<ul style="list-style-type: none">All studies published between January 1966 and November 2021, in the English language.Human participants >18 years old, of either sex or any ethnic background.Observational (e.g., cohort studies) reporting the risk of incident head and neck squamous cell carcinoma.Studies must have original data and report an adjusted odds ratios, risk ratio, hazard ratio (HR), or standardized incidence ratios (SIR) with their 95% CIs (or data to calculate them).Exposures: obesity, type 2 diabetes, hypertension, and dyslipidaemia, with definitions as described in the study protocol.Outcome: head and neck cancer (HNC) diagnosis in a major subsite i.e., oral cavity, oropharynx, larynx or hypopharynx, which may be human papilloma virus (HPV) positive or negative.	<ul style="list-style-type: none">The study is not based on incident head and neck squamous cell carcinoma, or contains only prevalent data, meaning a temporal relationship cannot be inferred e.g., case-control.Studies focused on cancer survival or progression.Studies with no original data or effect statistic reported. Continuous results to be discounted if they cannot be interpreted/ converted into categorical e.g., BMI >30.Human studies only, no <i>in vivo</i> animal or <i>in vitro</i> cell line studies.Studies of head and neck epithelial dysplasia, potentially malignant disease, or carcinoma <i>in situ</i>.Squamous cell carcinoma of other sites e.g., nasopharynx, salivary gland, oesophagus, skin, or lung due to differing aetiology, histological subtypes, and risk factors e.g., Epstein Barr Virus.

170


171 To ensure transparent and reproducible methodology, this study has been reported in line
172 with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)
173 statement and was pre-registered on International Prospective Register of Systematic
174 Reviews (PROSPERO) in 2021 (CRD42021250520). The protocol was also accepted for
175 publication in *BMJ Open* ³⁰.

176

177 *Data screening and extraction*

178 All titles and abstracts were initially screened by two authors (A.G. and C.R.) using
179 Covidence ²⁹. Any conflicts were resolved by a third independent reviewer (M.G.). A PRISMA
180 flowchart ³¹ representing the study selection process is shown in **Figure 1**. Full text of
181 articles included after title and abstract screening were retrieved and screened by (A.G., C.R.
182 and M.G.). Data were then extracted from articles which met the inclusion criteria (**Table 1**).
183 This was performed independently by three authors (E.G., C.R and M.G.) using a
184 standardised data collection spreadsheet containing: study ID; the first author's last name,
185 year of publication, study design, sample size, age and sex of the subjects, country of origin,
186 duration of follow-up in cohort studies, assessment of exposure and outcome, adjusted
187 covariates, number of cases, the effect estimates with 95% CIs and follow-up duration. From
188 each study, risk estimates were extracted which reflected the greatest degree of
189 adjustments for potential confounders. If study data appeared in more than one article, the
190 most recent publication or largest e.g., pooled result were extracted for the statistical
191 analysis.

192



193

194

195 **Figure 1.** PRISMA flowchart representing the publication selection process

196

197 *Exposure definitions*

198 There are differences in metabolic trait definitions used, depending on the country where
199 guidelines were written, age, sex, and ethnicity³²⁻³⁴. For this study, the following metabolic
200 traits definitions were used:

201

202 1) The WHO definition of obesity as body mass index (BMI) of ≥ 30 kg/m² must have been
203 used³⁵. BMI was acceptable if calculated from self-reported height and weight or taken
204 from medical records or measured at baseline.

205

206 2) The WHO defines type 2 diabetes as a chronic disease that occurs when the body cannot
207 effectively use the insulin it produces and is largely the result of excess body weight and
208 physical inactivity. Diagnosis was defined as symptoms such as polyuria or polydipsia, plus
209 ^{36,37}:

- 210 • a random blood plasma glucose concentration ≥ 11.1 mmol/l or;
- 211 • a fasting plasma glucose concentration ≥ 7.0 mmol/l (whole blood ≥ 6.1 mmol/l) or;
- 212 • two-hour plasma glucose concentration ≥ 11.1 mmol/l two hours after 75g
213 anhydrous glucose in an oral glucose tolerance test (OGTT) or;
- 214 • glycated haemoglobin (HbA1c) 6.5% or more (48 mmol/mol and above)

215 A diagnosis of type 2 diabetes via self-report, International Classification of Diseases (ICD)
216 codes or medical records was also accepted.

217

218 3) The WHO definition of hypertension as ³⁸:

- 219 • a systolic blood pressure (SBP) reading of ≥ 130 mmHg; and/or
- 220 • a diastolic blood pressure (DBP) readings on both days of ≥ 85 mmHg.

221 ICD-codes and patients taking antihypertensive medication were also acceptable diagnoses.

222

223 4) Dyslipidaemia classified as serum total cholesterol (TC), low density lipoprotein
224 cholesterol (LDL-C), triglycerides, apolipoprotein B, or lipoprotein(a) concentrations above
225 the 90th percentile, or high density lipoprotein cholesterol (HDL-C) or apolipoprotein
226 concentrations below the 10th percentile for the general population in which the study was
227 conducted ³⁹. ICD-codes and patients taking cholesterol-lowering medication were also
228 acceptable diagnoses.

229

230 *Outcome definitions*

231 All diagnoses of incident head and neck squamous cell carcinoma should have been
232 confirmed using histology by a trained pathologist and reported using appropriate ICD codes
233 ⁴⁰. Cancer cases for the disease of interest have the following ICD-10 codes: oral cavity
234 (C02.0 – C02.9, C03.0 – C03.9, C04.0 – C04.9, C05.0 – C06.9) oropharynx (C01.9, C02.4,
235 C09.0 – C10.9), hypopharynx (C13.0 – C13.9), overlapping (C14 and combination of other

236 sites) and 25 cases with unknown ICD code (other). Older versions of ICD code e.g., ICD-8
237 and 9 were also accepted.

238

239 *Quality assessment of studies*

240 This assessment was used in evaluating the strength of evidence from the included studies.
241 Three authors (A.G., C.R. and M.G.) independently assessed papers for risk of bias during
242 data extraction using the Risk of Bias in Non-randomised Studies – of Exposures (ROBINS-E)
243 tool (available at: <https://www.riskofbias.info/welcome/robins-e-tool>)⁴¹. The ROBINS-E tool
244 aims to assess the result of interest in an observational study for risk of bias, where that
245 study is designed to assess the effect of exposure on outcome ⁴². Pre-defined confounding
246 variables that were agreed, included: age, sex, smoking status, alcohol intake, ethnicity, and
247 socio-economic status. Further confounding variables that were recognised as important,
248 but possibly to a lesser extent, included: dietary intake, physical exercise, and other
249 metabolic traits (e.g., where BMI was the exposure, adjusting for hypertension,
250 dyslipidaemia, and type 2 diabetes). The ‘appropriateness’ of each study to address the
251 review question was also considered.

252

253 Data visualisations of the ROBINS-E tool were created using the *robvis* tool (available at:
254 <https://mcguinlu.shinyapps.io/robvis/>). An individual panel has been developed for each
255 individual exposure. Individual results from each included study were assessed using the
256 tool for each included study. There was no difference in risk of bias assessment within each
257 study and therefore the overall risk of bias assessment is presented below.

258

259 *Data analysis and synthesis*

260 The analysis and synthesis process were performed in two phases. The first phase consisted
261 of estimating the effect of each metabolic trait (obesity, type 2 diabetes, dyslipidaemia, and
262 hypertension) on incident HNC separately for each included study. All included studies were
263 cohort studies, with most using non-exposed comparisons and reporting risk (RR) and
264 hazard ratios (HR). Other studies using external general population comparisons reported
265 standardised incidence ratios (SIR). Because the absolute risk of HNC is low, all the above
266 measures yield similar estimates of RR and this approach has been taken previously in
267 similar head and neck cancer meta-analyses ¹⁷. The second phase focussed on estimating

268 the combined effect across studies using meta-analysis, using *metan* software in Stata
269 (*Stata Statistical Software: Release 16*. College Station, TX: StataCorp LLC). Summary effects
270 with their corresponding 95% CIs were derived using the method described by DerSimonian
271 and Laird for both fixed effects and random effects models, which incorporates between-
272 study variability⁴³. This was performed separately for each metabolic trait, with a
273 preference for random-effects if there is no important difference between the two
274 methods.

275

276 The analysis yielded information about the heterogeneity of effects across studies, using
277 Cochran's Q test and Higgins' I² statistic. To further explore the sources of heterogeneity,
278 subgroup, and meta-regression analyses were performed according to age, geographic
279 location, year of publication, methods of exposure assessment, length of follow-up, the
280 number of cancer cases and adjustment for confounding factors including age, sex, smoking
281 and alcohol use. Small study effects, which may reflect publication bias, study quality or
282 other sources of heterogeneity were assessed using funnel plots, which show effect
283 estimates from individual studies plotted against the standard error as a measure of each
284 study's size or precision. In the absence of bias and between study heterogeneity, the
285 scatter will be due to sampling variation alone, with the plot resembling a symmetrical
286 inverted funnel. Smaller studies will be scattered more widely at the bottom, with larger
287 studies nearer the top and any gaps where smaller studies are missing will be evident⁴⁴.
288 Sensitivity analyses were performed by excluding two large pooled analyses from the meta-
289 analyses, one for BMI¹¹ and the other for type 2 diabetes¹⁷, and calculating an estimate for
290 the remainder of the studies to evaluate whether the results were significantly affected by
291 these studies.

292

293 **Results**

294

295 The search generated 7,316 potential records of which 6,129 were screened following the
296 removal of 1,187 duplicates. Of these, 197 full-text articles of interest were assessed for
297 eligibility. One hundred and sixty one of these articles were subsequently excluded: 105 due
298 to study designs that could not infer a temporal relationship between the exposure and
299 outcome, 29 where the exposure was not relevant or as defined above, 16 in which the

300 outcome was not relevant or as defined above, 1 with an ineligible comparison group
301 (diabetics treated versus not treated), 7 with no original data or reported effect statistic
302 (e.g., short abstracts), 2 studies had continuous data only which was not comparable and 1
303 article that was not written in English. The remaining 36 eligible articles were included for
304 full qualitative and quantitative synthesis to investigate the association between metabolic
305 traits and HNC risk (**Figure 1**). One large pooled analysis for BMI ¹¹ included the results from
306 4 of the studies ⁴⁵⁻⁴⁸ and similarly, a pooled analysis for type 2 diabetes¹⁷ included the
307 results from 6 of the studies ^{9,49-53}, so only the two pooled analyses were represented in the
308 final **Table 2** and subsequent analyses.

309

310 Eight studies reported the association between BMI (n= 2,859 cases) and risk of HNC ^{11,12,14-}
311 ^{16,54-56}, with 15 studies reporting the association with type 2 diabetes (n= 17,582 cases) ^{12,17-}
312 ^{20,23,24,57-64}, six studies hypertension (n= 12,151 cases) ^{12,19-23}, and four studies dyslipidaemia
313 (n= 6,410 cases) ^{12,19,20,65} and HNC risk (**Table 2**). Adjustments were made for potential
314 confounders of two or more factors, including age, in all studies.

315

316 **Obesity and risk of HNC**

317 In the analysis of five studies investigating the association between obesity and incidence of
318 combined head and neck cancer sites, there was an overall RR of 1.06 (95%CI (0.76, 1.49))
319 using a random-effects model, little evidence of an effect (**Figure 2a**). The result was similar
320 when using a fixed-effects model (RR= 1.10, 95%CI (0.97, 1.25)). There was however
321 evidence for the presence of substantial heterogeneity between studies (*P* heterogeneity
322 <0.024, *I*²= 73.2%) (**Figure 2a**). With respect to individual subsites, there was again little
323 evidence of an association of obesity on oral cavity (RR= 0.92, 95%CI (0.81, 1.04)),
324 oropharyngeal (RR= 1.05, 95%CI (0.69, 1.59)), or laryngeal (RR= 0.95, 95%CI (0.81, 1.11))
325 cancer using a random-effects model. There were similar results when using a fixed-effects
326 model (**Figure 2b – d**).

First Author/ Year/ Country	Study design	Sample size, age (years), sex	Exposure	Method of exposure assessment	Method of outcome assessment	Adjusted covariates	Outcome (subsite)	Exposed cases	Reported Statistic	Effect size	95% CI	Follow- up (years)
Obesity												
Samanic/2006/ Sweden ⁵⁴	Prospective cohort	N= 362,552 Age (mean): 34 Male: 100%	BMI > 30	Measured at baseline	ICD-7 codes	age, smoking status, year	Larynx	17	RR	0.94	0.57 - 1.56	19
Bhaskaran/ 2013/ UK ⁵⁵	Prospective cohort	N= 5,243,978 Age (median, IQR): 38 (27-54) Male: 45%	BMI > 30 - 34.9 BMI > 35	MR	ICD-10 codes	age, sex	Oral cavity Oral cavity	1147 310	HR	0.81 0.82	0.63 - 1.03 0.57 - 1.2	6 (3-11)
Gaudet/ 2015/USA ^{11*}	Pooled analysis	N= 1,941,300 Age (mean): 55 Male: 41%	BMI >30	SR/ or measured at baseline	ICD-10 codes, SR, MR, and state cancer registries	age, sex, education, cohort, alcohol, genetic ancestry	Head and Neck cancer combined	297	HR	1.40	1.08-1.81	> 1
Maasland/ 2015/ Netherlands ⁵⁶	Prospective cohort	N= 3,980 Age (mean, SD): 61 (4) Male: 49%	BMI > 30	SR	ICD-9 codes	age, sex, cigarette smoking, alcohol	Head and Neck cancer combined Oral cavity Larynx	11 6 5	RR	0.52 0.76 0.72	0.24 - 1.14 0.28 - 2.04 0.27 - 1.92	2-20.3
Ward/ 2017/ European ¹⁶	Prospective cohort	N= 363,094 Age (range): 25- 70 Male: 35%	BMI > 30	SR/ or measured at baseline	ICD-10 codes	age, sex, recruitment centre, smoking status, alcohol, education	Oral cavity (male) Oropharynx (male)	19 14	HR	1.12 0.69	0.58 - 2.13 0.36 - 1.30	15.1

			BMI >30				Hypopharynx (male)	8		0.68	0.28 - 1.67	
							Larynx (male)	45		0.91	0.60 - 1.36	
							Oral cavity (female)	23		1.42	0.79 - 2.54	
							Oropharynx (female)	11		2.03	0.88 - 4.65	
							Hypopharynx (female)	0		NA	NA	
							Larynx (female)	4		0.6	0.20 - 1.85	
Gribsholt/ 2020/ Denmark ¹⁵	Prospective cohort	N= 313,321 Age (median): 43 Male: 27%	BMI > 30	MR	ICD-8; ICD-10 codes	age, sex, year of diagnosis	Oropharynx	154	SIR	1.02	0.86 - 1.19	6.7
							Larynx	116		0.98	0.81 - 1.18	
							Oral cavity	100		0.93	0.76 - 1.13	
Cao/ 2020/ UK ¹⁴	Prospective cohort	N= 390,575 Age (mean, SD): 56 (8) Male: 47%	BMI > 30	Measured at baseline	ICD-10 codes	age, sex, ethnicity, Townsend deprivation index, qualification, employment status, alcohol intake, smoking status	Oral cavity	268	HR	1.02	0.74 - 1.40	7.8

Jiang/ 2021/ UK ¹²	Prospective cohort	N= 474,929 Age (mean, SD): 56 (8) Male: 46%	Central Obesity/ BMI >30	Measured at baseline	ICD-10 codes	age, sex, education, ethnicity, index of multiple deprivation, alcohol consumption, smoking status, physical activity, fruit, and vegetable intake, NSAIDs use, CRP	Head and Neck cancer combined	304	HR	1.04	0.90 - 1.21	6.2 (+/- 1.2)
Type 2 Diabetes												
Chodick/ 2010/ Israel ⁵⁷	Retrospective cohort	N= 100,595 Age (mean, SD): 62 (13) Male: 53%	Diabetes mellitus	MR	ICD-9 codes	age, region, socioeconomic status, use of healthcare services a year prior to index date, body mass index, history of cardiovascular diseases	Head and Neck cancer combined (male)	20	HR	0.90	0.54 - 1.48	8 (2.5)
							Head and Neck cancer combined (female)	8		0.61	0.28 - 1.27	
Atchison/ 2011/ USA ⁵⁸	Prospective cohort	N= 4,501,578 Age (median): 55 Male: 100%	Diabetes mellitus	ICD-8 and ICD-9 codes	ICD-8 and 9 codes	smoking, alcohol, obesity via surrogate variables	Oral cavity (buccal site)	3036	RR	0.85	0.82 - 0.89	11.2
							Larynx	1413		0.76	0.71 - 0.8	
Lo/ 2013/ Taiwan ⁵⁹	Prospective cohort	N= 1,790,868 Age (mean, SD): 61 (14) Male: 49%	Type 2 diabetes mellitus	ICD-9 codes/ MR	ICD-9	age, sex, urbanisation, hypertension, dyslipidaemia	Head and Neck cancer combined	3750	HR	1.21	1.13 - 1.30	3.5

Walker/ 2013/ (UK, Scotland) ⁶⁰	Prospective cohort	N= 81,018 Age (range): 55-79 Male: 45%	Type 2 diabetes mellitus	MR	ICD-10 codes	age, socioeconomic status	Head and Neck cancer combined (male)	NA	HR	0.77	0.61 - 0.98	6
							Head and Neck cancer combined (female)	NA	HR	0.90	0.60 - 1.34	
Nakamura/ 2013/ Japan ⁶¹	Prospective cohort	N= 30,720 Age (mean, SD): M= 54 (12) F= 56 (13) Male: 46%	Type 2 diabetes mellitus using cut-off of age >30 years	SR/ 214 cases confirmed HbA1c ≥6.1% based on the diagnostic criteria set by the Japan Diabetes Society	ICD-10 codes	age, smoking status, body mass index, physical activity, length of education in years, history of hypertension, history of stroke, history of ischemic heart disease, total energy intake, intake of fat, ethanol, coffee	Larynx (male)	4	HR	3.61	1.16 - 11.2	16
							Larynx (female)	NA		NA	NA	
Lin/ 2014/ Taiwan ⁶²	Prospective cohort	N= 9,884,228 Age: >20 Male: 55%	Type 2 diabetes mellitus	ICD-codes/ MR	ICD-9 codes	age, insurance premium, urbanisation	Oral cavity (male)	2411	SIR	1.09	1.03 - 1.15	10
							Oral cavity (female)	733		1.08	0.94 - 1.25	
Tseng/ 2014/ Taiwan ²⁴	Prospective cohort	N= 89,089 Age (mean, SD): 55 (15) Male: 53%	Type 2 diabetes mellitus	ICD-9 codes	ICD-9 codes and histologically confirmed	age, sex, hypertension, hyperlipidaemia, coronary artery disease, chronic kidney	Head and Neck cancer combined	634	HR	1.48	1.31 - 1.67	15

						disease, obesity, geographic region, monthly income						
							Oral cavity	362		1.74	1.47 - 2.06	
							Oropharynx	56		1.53	1.01 - 2.31	
							Larynx	44		1.03	0.68 - 1.56	
							Hypopharynx	58		0.99	0.69 - 2.89	
Gong/ 2015/ European ^{17*}	Pooled cohort	N= 5,535,615 Age (range): 30-71 Male: 46%	Type 2 diabetes mellitus	MR/ SR	ICD-codes/ MR	age, sex, calendar year, body mass index, smoking, alcohol use, district of residence, physical activity, NSAIDs use, family history of cancer, endoscopy history, hypertension, ischaemic heart disease, race, education, marital status, health status, dietary intake of red meat, white meat, fruits, vegetables, coffee, multivitamin use	Oral cavity and oral-pharyngeal cancer	3002	RR	1.15	1.02 - 1.29	8.6-35
He/ 2018/ China ⁶³	Retrospective cohort	N= 793,795 Age (mean, SD): 43 (15) Male: 52%	Type 2 diabetes mellitus (new onset)	MR	ICD-10 codes	age, sex, comorbidities, concomitant medication, hospitallisations, cancer-related detection examinations, number of outpatient visits	Head and Neck cancer combined	35	HR	2.09	1.23 - 3.56	5
Saarela/ 2019/ Finland ¹⁸	Prospective cohort	N= 428,326 Age: >30 Male: 48%	Type 2 diabetes mellitus	MR	ICD-10 codes	NA	Oral cavity	308	SIR	1.14	1.01 - 1.26	10.5

						NA	Oropharynx	233		0.95	0.83 - 1.07	
						NA	Larynx	263		0.9	0.79 - 1.00	
Kim/ 2019/ Korea ²⁰	Prospective cohort	N= 23,253,270 Age (mean, SD): 48 (14) Male: 49%	Type 2 diabetes mellitus	Fasting blood glucose measured >100mg/dL	ICD-codes	age, sex, smoking, alcohol, exercise	Larynx	2608	RR	1.12	1.06 - 1.19	7
Qi/ 2019/ China ⁶⁴	Retrospective cohort	N= 410,191 Age (mean, SD): 62 (14) Male: 50%	Type 2 diabetes mellitus	MR	ICD-10 codes	age, sex	Larynx	NA	SIR	0.95	0.65 - 1.25	3
Seo/ 2020/ Korea ²³	Prospective cohort	N= 9,746,606 Age (mean): 51 Male: 55%	Type 2 diabetes mellitus	Measured at baseline/ MR prescription of antidiabetic drugs	ICD-codes	age, sex, smoking status, alcohol intake, exercise, body mass index	Oral cavity Larynx	320 160	HR	1.1 1.2	0.98 - 1.24 1.02 - 1.42	7
Jiang/ 2021/ UK ¹²	Prospective cohort	N= 474,929 Age (range): 37-73 Male: 46%	Type 2 diabetes mellitus	Fasting plasma glucose measured >5.5mmol/L/ SR	ICD-10 codes	age, sex, education, ethnicity, index of multiple deprivation, alcohol consumption, smoking status, physical activity, fruit, and vegetable intake, NSAIDs use, CRP	Head and Neck cancer combined	174	HR	1.22	1.02 - 1.45	6.6 (1.2)
Kim/ 2021/ Korea ¹⁹	Prospective cohort	N= 6,757,048 Age (mean, SD): 49 (13)	Type 2 diabetes mellitus	Fasting blood glucose measured > 100 mg/dL or the	ICD-10 codes	age, sex, smoking status, alcohol intake, exercise, body mass index	Larynx	675	HR	1.25	1.12 - 1.40	6.4

Male: 43%
 use of
 hypoglycaemic
 agent

Hypertension

Stocks/ 2012/ European ²¹	Prospective cohort	N= 577,799 Age (mean): 44 Male: 50%	Hypertension	Measured at baseline (increased blood pressure per 10mmHg)	ICD-7 codes	age, sex, stratified by cohort, body mass index, smoking	Oral cavity and Oropharynx (male)	561	HR	1.31	1.15 - 1.48	12
							Oral cavity and Oropharynx (female)	177	HR	1.05	0.85 - 1.28	
Kim/ 2019/ Korea ²⁰	Prospective cohort	N= 23,253,270 Age (mean, SD): 48 (14) Male: 49	Hypertension	Measured at baseline SBP >130 or DBP >85mmHg	ICD-codes	age, sex, smoking, alcohol, exercise	Larynx	3565	HR	1.12	1.06 - 1.19	7
Christakoudi/ 2020/ European ²²	Prospective cohort	N= 307,318 Age (mean, SD): 53 Male: 37%	Hypertension	Measured at baseline SBP ≥140 mmHg, or DBP ≥90 mmHg/ SR	ICD-codes	age, sex, body mass index, diabetes mellitus, education, physical activity, smoking status, alcohol intake, fruit consumption, vegetable consumption, red meat consumption	Head and Neck cancer combined	382	HR	1.21	1.03 - 1.42	13.7 (4.4)
							Oral cavity and Oropharynx	180		1.15	0.91 - 1.45	
							Larynx	142		1.37	1.04 - 1.80	

Seo/ 2020/ Korea ²³	Prospective cohort	N= 9,746,606 Age (mean): 51 Male: 55%	Hypertension	Measured at baseline SBP >140 or DBP >90mmHg	ICD-codes via insurance system	age, sex, smoking status, alcohol intake, exercise, body mass index, diabetes mellitus	Oral cavity	2535	HR	1.11	1.04 - 1.17	7
							Larynx	1301		1.23	1.13 - 1.33	
Jiang/ 2021/ UK ¹²	Prospective cohort	N= 474,929 Age (range): 37-73 Male: 46%	Hypertension	Measured at baseline SBP >130 or DBP >85mmHg/ SR on treatment with antihypertensives	ICD-10 codes	age, sex, education, ethnicity, index of multiple deprivation, alcohol consumption, smoking status, physical activity, fruit, and vegetable intake, NSAIDs use, CRP	Head and Neck cancer combined	160	HR	1.00	0.82 - 1.20	6.5
Kim/ 2021/ Korea ¹⁹	Prospective cohort	N= 6,757,048 Age (mean): 49 Male: 43%	Hypertension	Measured at baseline SBP >130 or DBP >85mmHg/ SR on treatment with antihypertensives	ICD-10 codes	age, sex, smoking status, alcohol intake, exercise, body mass index	Larynx	681	HR	1.16	1.04 - 1.30	6.4
Dyslipidaemia												
Chyou/ 1992/ Hawaii ⁶⁵	Prospective cohort	N= 7,716 Age-adjusted Male: 100%	Serum cholesterol (200-234 mg/dl)	Measured serum cholesterol (mg/dl)	ICD-8 codes	age, smoking, alcohol	Oral cavity and Oropharynx	6	RR	0.52	0.19 - 1.44	22
			Serum cholesterol (235+ mg/dl)				Oral cavity and Oropharynx	4	RR	0.38	0.12 - 1.26	

Kim/ 2019/ Korea ²⁰	Prospective cohort	N= 23,253,270 Age (mean, SD): 48 (14) Male: 49%	Low HDL cholesterol	Measured HDL cholesterol <40 mg/dL for men and <50 mg/dL for women	ICD-10 codes	age, sex, smoking, alcohol, exercise	Larynx	1700	HR	1.09	1.03 - 1.15	7
			High triglyceride	Measured triglyceride ≥ 150 mg/dL		age, sex, smoking, alcohol, exercise	Larynx	2484	HR	1.09	1.04 - 1.15	
Jiang/ 2021/ UK ¹²	Prospective cohort	N= 474,929 Age (range): 37-73 Male: 46%	Low HDL cholesterol	Measured HDL <1.0mmol/L for men and <1.30mmol/L for women	ICD-10 codes	age, sex, education, ethnicity, index of multiple deprivation, alcohol consumption, smoking status, physical activity, fruit, and vegetable intake, NSAIDs use, CRP	Head and Neck cancer combined	464	HR	1.01	0.84 - 1.22	6.5
			High triglyceride	Measured at baseline >1.7mmol/L/ or SR on treatment with cholesterol-lowering medications		Head and Neck cancer combined	665	HR	0.95	0.81 - 1.10		
Kim/ 2021/ Korea ¹⁹	Prospective cohort	N= 6,757,048 Age (mean): 49 Male: 43%	High triglyceride	Measured triglyceride ≥ 150 mg/dL	ICD-10 codes	age, sex, smoking status, alcohol intake, exercise, body mass index	Larynx	653	HR	1.16	1.04 - 1.30	6.4
			Low HDL cholesterol	Measured HDL cholesterol <40 mg/dL for men and		Larynx	434	HR	1.15	1.02 - 1.29		

<50 mg/dL for
women

327

Table 2. Descriptive characteristics of studies of metabolic traits and risk of head and neck cancer

329

330 Key: SR, self-report; MR, medical report; ICD, International Classification of Disease codes; RR, risk ratio; HR, Hazard ratio; SIR, standardised incidence ratio; BMI, body mass
331 index; HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; SES, socio-economic status.


332

333 * Pooled analyses Gaudet et al. includes effect estimates for Andreotti et al. (2010),⁴⁵ Gaudet et al. (2012),⁴⁶ Hashibe et al. (2013),⁴⁷ Etemadi et al. (2014).⁴⁸

334 * Pooled analysis for Gong et al. includes effect estimates for Hjalgrim et al. (1997),⁴⁹ Wideroff et al. (1997),⁵⁰ Stocks et al. (2009),⁵¹ Wotton et al. (2011),⁹ Tseng et al.

335 (2013),⁵² Lai et al. (2013).⁵³

336 **Figure 2. Relative risks for the association between obesity and incidence of head and neck cancer**
 337 **combined and by subsite**



Key: DL, DerSimonian and Laird random-effects model; IV, inverse variance weighted fixed-effects model.


369

370 **Type 2 diabetes mellitus and risk of HNC**

371 In the analysis of 6 studies on the association between type 2 diabetes and incidence of
 372 combined head and neck cancer, there was an overall RR of 1.13 (95%CI (0.95, 1.34)) using a
 373 random-effects model. Strong evidence of heterogeneity was present between studies (P
 374 heterogeneity= <0.0001, $I^2= 80.0\%$) (**Figure 3a**). There was a trend towards an increased risk
 375 association with oral cavity (RR= 1.13, 95%CI (0.97, 1.31)), oropharyngeal (RR= 1.16, 95%CI
 376 (0.73, 1.83)) and laryngeal (RR= 1.05, 95%CI (0.87, 1.26)) cancer using a random effects
 377 model, but again all results crossed the null, with strong evidence of heterogeneity across all
 378 subsites (**Figure 3b – d**). When using a fixed effects model, the result for combined head and
 379 neck cancer sites showed a stronger increased risk effect (RR= 1.22, 95%CI (1.16, 1.29)), but
 380 attenuated towards the null in the individual subsites.


381

382 **Figure 3. Relative risks for the association between type 2 diabetes mellitus and incidence of head**
 383 **and neck cancer combined and by subsite**




384

385




392

393



394



395

396




Key: DL, DerSimonian and Laird random-effects model; IV, inverse variance weighted fixed-effects model.

397

398 Hypertension and risk of HNC

399 In the analysis of only 2 studies on the association between hypertension and incidence of
 400 combined head and neck cancer, there was limited evidence of an increased risk (RR= 1.11,
 401 95%CI (0.92, 1.33)) using a random-effects model. There was evidence of substantial
 402 heterogeneity among studies (P heterogeneity= 0.134, $I^2= 55.6\%$) (**Figure 4a**). An increased
 403 risk of hypertension was consistent across HNC subsites, with a RR of 1.16 (95%CI (1.05,
 404 1.28)) found for combined oral cavity and oropharyngeal cancer, and the strongest effect
 405 found in the larynx (RR= 1.17, 95%CI (1.10, 1.25)) (**Figure 4b – c**). The amount of
 406 heterogeneity was similar in both oral cavity and oropharyngeal combined (P
 407 heterogeneity= 0.108, $I^2= 50.6\%$) and laryngeal cancer analyses (P heterogeneity= 0.186, $I^2=$
 408 37.7%). The results remained similar when using a fixed effects model across all sites.
 409

410 **Figure 4.** Relative risks for the association between hypertension and incidence of head and neck
 411 cancer combined and by subsite



414
 415 Key: DL, DerSimonian and Laird random-effects model; IV, inverse variance weighted fixed-effects model.



416
 417 **Dyslipidaemia and risk of HNC**

418 There were only 2 studies available for meta-analysis, both investigating the effect of
 419 dyslipidaemia on incident laryngeal cancer risk. There was some evidence of an increased

420 risk association of both low HDL (RR= 1.12, 95%CI (1.07, 1.18)) and high triglyceride levels
 421 (RR= 1.10, 95%CI (1.05, 1.15)) using a random-effects model (Error! Not a valid bookmark
 422 self-reference.a – b). In the low HDL analysis, there was evidence of moderate
 423 heterogeneity (P heterogeneity= 0.103, $I^2= 62.5\%$), which was not found in the high
 424 triglycerides analysis (P heterogeneity= 0.319, $I^2= 0.0\%$) (Error! Not a valid bookmark self-
 425 reference.a – b). The results remained similar when using a fixed effects model across all
 426 sites. These findings were not supported in the single study by Jiang *et al.*¹² which
 427 investigated low HDL (RR= 1.01, 95%CI (0.84, 1.22)) and high triglycerides (RR= 0.95, 95%CI
 428 (0.81, 1.10)) on head and neck combined cancer (Table 2).

429

430 **Figure 5. Relative risks for the association between dyslipidaemia and incidence of laryngeal cancer**



434

435

436 **Key:** Risk ratios for the association between a. low high density lipoprotein/ b. high triglycerides and
 437 incidence of laryngeal cancer. DL, DerSimonian and Laird random-effects model; IV, inverse variance
 438 weighted fixed-effects model.

439

440

441

442 *Subgroup analyses*

443 Pre-defined subgroup meta-analyses were conducted for all four metabolic traits according
444 to age, geographic location, year of publication, methods of exposure assessment, risk of
445 bias score, length of follow-up, the number of cancer cases and adjustment for confounding
446 factors including age, sex, smoking and alcohol use (**Supplementary Table 3**).

447

448 Stratifying by geographic location of the study resulted in a difference for both obesity
449 (European (RR= 0.97, 95%CI (0.90, 1.04)) vs USA (RR= 1.40, 95%CI (1.08, 1.81), *P* difference=
450 0.007), type 2 diabetes (Asian (RR= 1.23, 95%CI (1.13, 1.33)) vs European (RR= 1.00, 95%CI
451 (0.90, 1.12)) vs USA (RR= 0.81, 95%CI (0.72, 0.90), *P* difference <0.0001) and dyslipidaemia
452 (Asian (RR= 1.12, 95%CI (1.08, 1.16) vs European (RR= 0.97, 95%CI (0.87, 1.10) vs USA (RR=
453 0.45, 95%CI (0.21, 0.98), *P* difference= 0.006). Various methods of exposure assessment did
454 result in a differences for both obesity and type 2 diabetes. Within obesity, there were
455 differences between the use of medical records (RR= 0.94, 95%CI (0.86, 1.04) vs self-report
456 (RR= 0.63, 95%CI (0.38, 1.06)) vs measurements taken at baseline (RR= 1.02, 95%CI (0.91,
457 1.15)) vs a combination of the aforementioned methods (RR= 1.40, 95%CI (1.08, 1.81)) (*P*
458 difference = 0.011).

459

460 When stratifying by year of publication (before or after 2010), by adjustment for
461 confounding factors, length of follow-up and number of cancer cases, this resulted in
462 differences only within dyslipidaemia. However, there was only one small study by Chyou *et*
463 *al.* (1992)⁶⁵ representing the before 2010, no adjustment, >10 year follow-up and <50
464 cancer cases categories which is of high risk of bias.

465

466 *Risk of bias assessment*

467 Risk of bias assessment was undertaken using the Risk of Bias In Non-randomized Studies –
468 of Exposure (ROBINS-E) tool ⁴². From all included studies, each result (n= 85) included in the
469 meta-analysis was individually risk assessed across the seven domains of bias, accounting
470 for confounding variables which were pre-defined as important (i.e., age, sex, smoking
471 status, alcohol intake, ethnicity, and socio-economic status). There was no difference
472 between individual results within each study, therefore the overall study ratings only are

473 presented in **Supplementary Figures 1 – 4**. One study was rated as ‘Very high’ risk of bias
474 (3.7%)¹⁸, 21 studies were rated as ‘High’ (77.8%)^{15-17,19-24,54-65}, one study as ‘Some concerns’
475 (3.7%)⁶⁶ and the remaining studies as ‘Low’ (14.8%)^{12,14}. All ‘High’ and ‘Very high’ ratings
476 were due to bias that arose due to inadequate adjustment for confounding and/or the
477 handling of missing data.


478
479 Funnel plots for each metabolic trait were used to assess asymmetry which may be as a
480 result of true heterogeneity, poor methodological quality in smaller studies, reporting or
481 publication bias⁴⁴. For obesity, there appeared to be only limited asymmetry, with only one
482 outlier by Gaudet *et al.*¹¹ and potential smaller studies missing from the bottom right corner
483 (**Figure 6a**). For type 2 diabetes mellitus, there were significantly more larger studies, many
484 of which lay outside the 95%CI suggesting the presence of heterogeneity. There were eight
485 results from several studies which appear to be outliers in the type 2 diabetes funnel plot,
486 including results from Atchison *et al.*⁵⁸, Lo *et al.*⁵⁹, Tseng *et al.*²⁴, Lin *et al.*⁶², and Kim *et al.*
487^{19,20}. Four out of five of these outlier studies were distinct in that they were conducted in
488 Asian only populations (**Figure 6b**). There were too few (≤ 10) studies for hypertension and
489 dyslipidaemia) to confidently distinguish true asymmetry (**Figure 6c-d**).

490
491


492 **Figure 6.** Funnel plots showing effect estimates for metabolic traits on overall head and neck cancer
493 risk (all subsites)

494

494 **a. Obesity**



b. Type 2 diabetes mellitus



502

503 **c. Hypertension**


504

505

506

507


508



509

510

d. Dyslipidaemia



511 *Key: Estimated θ_{IV} (red) line is centred on a fixed effect summary estimate; 95% confidence intervals (95%CI)*
512 *(dashed lines) either side will include 95% of studies if no bias is present and the fixed effect assumption (that*
513 *the true treatment effect is the same in each study) is valid. Solid (red) line of no effect.*

514
515 **Sensitivity analyses**

516 No association was found when dropping the largest pooled analysis by Gaudet *et al.*¹¹ for
517 obesity in combined head and neck cancer (RR= 0.82, 95%CI (0.43, 1.56) with evidence again
518 for heterogeneity ($I^2 = 65.9\%$, P heterogeneity = 0.087). This lack of effect for obesity was
519 consistent across subsites, with results all crossing the null. Similarly, there was no
520 difference in the effect of type 2 diabetes on oral cancer risk when leaving out the other
521 large pooled analysis by Gong *et al.*¹⁷ (RR= 0.98, 95%CI (0.95, 1.01), with no change in
522 evidence for substantial heterogeneity ($I^2 = 95.8\%$, P heterogeneity = <0.001).

523
524 **Discussion**

525
526 This is the most comprehensive and up-to-date systematic review and meta-analysis on this
527 topic, considering the association of metabolic traits on HNC across subsites at a global
528 population level. Despite observations from individual studies suggesting an association
529 between BMI and HNC, no effect was found within any subsite in this study, using random-

530 effects meta-analyses (**Figure 2**). There was also limited evidence of an association for type
531 2 diabetes (**Figure 3**), but perhaps a trend towards increased risk for overall HNC, which is in
532 keeping with previous pooled estimates^{12,19,20,59}. Conversely, there was evidence of an
533 increased HNC risk for both hypertension and dyslipidaemia across subsites, but with fewer
534 studies included in these meta-analyses (**Figure 4 &**

535 **Dyslipidaemia and risk of HNC**

536 There were only 2 studies available for meta-analysis, both investigating the effect of
537 dyslipidaemia on incident laryngeal cancer risk. There was some evidence of an increased
538 risk association of both low HDL (RR= 1.12, 95%CI (1.07, 1.18)) and high triglyceride levels
539 (RR= 1.10, 95%CI (1.05, 1.15)) using a random-effects model (Error! Not a valid bookmark
540 self-reference.**a – b**). In the low HDL analysis, there was evidence of moderate
541 heterogeneity (P heterogeneity= 0.103, I^2 = 62.5%), which was not found in the high
542 triglycerides analysis (P heterogeneity= 0.319, I^2 = 0.0%) (Error! Not a valid bookmark self-
543 reference.**a – b**). The results remained similar when using a fixed effects model across all
544 sites. These findings were not supported in the single study by Jiang *et al.*¹² which
545 investigated low HDL (RR= 1.01, 95%CI (0.84, 1.22)) and high triglycerides (RR= 0.95, 95%CI
546 (0.81, 1.10)) on head and neck combined cancer (**Table 2**).

547
548 **Figure 5**). Furthermore, over 80% of studies were judged to be at ‘Very High’ or ‘High’ risk of
549 bias using the ROBINS-E tool (**Supplementary Figures 1 – 4**), so caution must be exercised
550 when interpreting these results. Of those studies assessed as low risk of bias, their results
551 suggest limited evidence for an effect of obesity, but an increased risk association of type 2
552 diabetes¹² on HNC risk. Conversely, this was not the case for hypertension and
553 dyslipidaemia, where the one study assessed as low risk of bias for these traits did not
554 provide evidence of an effect on HNC risk¹². Variability in the individual study results may
555 exist due to differences in timing of exposure measurement, confounder adjustment, or
556 from other sources of bias.

557
558 An apparent obesity paradox demonstrated in individual studies^{55,67} might be explained by
559 BMI as a collider acting as a form of selection bias⁶⁸. While tobacco smoking is correlated
560 with obesity, this may be dose dependant and change following smoking cessation⁶⁹.
561 Furthermore, many HNC patients are more likely to be underweight at presentation,

562 particularly those with alcohol use disorders, often correlated with heavy smoking
563 behaviour. Variability in the results may exist due to differences in timing of the exposure
564 measurement, whereby misclassification of participants into the wrong BMI category could
565 have occurred. This is because around one-third to a half of HNC patients experience
566 between 5 – 10% weight loss during the period prior to diagnosis ⁷⁰. Obesity may also
567 provide additional nutritional reserves giving patients a survival advantage, if for example
568 there was latent tumour progression prior to the baseline diagnosis in these observational
569 studies. There may be issues with measurement error again leading to misclassification in
570 this study, given BMI is simply a function of mass and height and does not specifically
571 indicate metabolically unhealthy adiposity or take into account lean muscle mass. In future,
572 more accurate measures body composition such as bioelectrical impedance or dual-energy
573 X-ray absorptiometry (DEXA) scanning could be used to better differentiate fat mass from
574 lean tissue. This study also lacked detail on HPV status or tumour stage, with more
575 advanced stage disease likely resulting in more significant weight loss ⁷¹. Subgroup
576 differences were found across metabolic traits with respect to geographic location. Stronger
577 effects were found for obesity in USA compared with the UK, and for both type 2 diabetes
578 and dyslipidaemia in Asian populations compared with the other continents, which is in
579 keeping with global epidemiology ^{72,73}. Larger subgroup effects were also found when
580 patient's self-reported their diagnoses compared to researchers using medical records,
581 suggesting recall bias may be present.

582

583 *Strengths and limitations of this study*

584 This meta-analysis includes the largest available studies, resulting in a sample size of n=
585 39,002 HNC cases in a total population size of over 84 million. This suggests the study was
586 well powered to detect any association between metabolic traits and HNC, however there
587 were fewer studies for hypertension and dyslipidaemia compared to the other traits. As
588 there were <10 studies in these analysis, a comprehensive assessment of publication or
589 reporting bias could not be made. However, the lack of smaller positive or negative effect
590 studies for type 2 diabetes suggests potential publication or reporting bias. Both the obesity
591 and type 2 diabetes funnel plots revealed outlier results. Leaving out the two outlier studies
592 in the obesity meta-analysis had little effect on the overall null finding. Evidence of
593 substantial heterogeneity was present (I^2 values >50%) between studies across all metabolic

594 traits, which increased when combining HNC subsites as would be expected. In particular for
595 type 2 diabetes whereby four out of five outlier studies were in Asian only populations. This
596 could be due to the differences in HNC aetiology in Asia e.g., betel quid chewing. Future
597 work should include meta-analysing studies separately by geographic region or restricting to
598 particular populations, as this appears to be a clear source of heterogeneity. Other forms of
599 bias such as collider, recall and information bias may have been present, as described in the
600 previous section. Despite multivariable adjustment within studies, residual confounding
601 may still exist, given that HNC risk factors, such as smoking, alcohol and socioeconomic
602 status are difficult to fully account for. While we conducted a number of subgroup analyses,
603 there was insufficient data in the included studies to examine the effect of sex. This may
604 have been important as previous analyses have suggested that the effect of type 2 diabetes
605 on HNC was mainly found in females ¹⁷, which may indicate poorer metabolic control,
606 elevated exposure to insulin and subsequent oxidative DNA damage. There were limited
607 data for smoking at specific subsites across the metabolic traits and therefore meta-analysis
608 at this level was not possible.

609

610 **Conclusions**

611

612 The meta-analysis performed in this study suggested there was limited evidence for an
613 association between obesity or type 2 diabetes and HNC risk. However, there was some
614 evidence for increased risk associations with hypertension and dyslipidaemia. These
615 observational associations are susceptible to confounding, bias and reverse causality and
616 results must be interpreted with caution given the high risk of bias detected.

617

618

619 **Authors' contributions**

620

621 AG and CR jointly contributed to the development of the protocol, and the drafting, writing
622 and editing of this manuscript. FS contributed to the development of this study and editing
623 of the manuscript. JH contributed to the development of the search strategy. BM, EG, EV,

624 RR and JPTH contributed to the development of this study. MG was responsible for
625 conceptualising this study, drafting and editing this manuscript. All authors contributed to
626 the development of the search strategy. All authors have approved and contributed to the
627 final written manuscript.

628

629 **Funding statement**

630

631 A.G. is a National Institute for Health and Care Research (NIHR) doctoral research fellow
632 (NIHR302605). C.R. is currently supported by a Wellcome Trust GW4-Clinical Academic
633 Training PhD Fellowship. F.S. was supported by a Cancer Research UK (C18281/A29019)
634 programme grant (the Integrative Cancer Epidemiology Programme). E.E.V is supported by
635 Diabetes UK (17/0005587). E.E.V is also supported by the World Cancer Research Fund
636 (WCRF UK), as part of the World Cancer Research Fund International grant programme
637 (IIG_2019_2009). R.C.R. is a de Pass VC research fellow at the University of Bristol (no grant
638 number). J.P.T.H supported by the NIHR Biomedical Research Centre at University Hospitals
639 Bristol and Weston NHS Foundation Trust and the University of Bristol (no grant number),
640 the NIHR Applied Research Collaboration West at University Hospitals Bristol and Weston
641 NHS Foundation Trust (no grant number) and is a National Institute for Health Research
642 (NIHR) Senior Investigator (no grant number). M.G. was supported by a Wellcome Trust
643 GW4-Clinical Academic Training PhD Fellowship. This research was funded in part, by the
644 Wellcome Trust [Grant number 220530/Z/20/Z]. For the purpose of Open Access, the author
645 has applied a CC BY public copyright licence to any Author Accepted Manuscript version
646 arising from this submission. The views expressed in this publication are those of the
647 author(s) and not necessarily those of Wellcome, NIHR, the NHS or Department of Health.

648

649 **Competing interests statement**

650

651 None declared

652

653 **Patient and Public Involvement**

654

655 Patients and/or the public were not involved in the development, conduct or proposed

656 dissemination of this systematic review protocol.

657

658 **Word Count:** 1,956 (excluding abstract)

659

660 **References**

661

662 1 Office for National Statistics. *Data for 1974 onwards: Office for National Statistics.*

663 *Adult Smoking habits in Great Britain.* ,

664 <<https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/dru>

665 [gusealcoholandsmoking/datasets/adultsmokinghabitsingreatbritain](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/drugusealcoholandsmoking/datasets/adultsmokinghabitsingreatbritain).> (2020).

666 2 Sung, H. *et al.* Global cancer statistics 2020: GLOBOCAN estimates of incidence and

667 mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for*

668 *Clinicians*, doi:<https://doi.org/10.3322/caac.21660> (2021).

669 3 Johnson, D. E. *et al.* Head and neck squamous cell carcinoma. *Nature Reviews*

670 *Disease Primers* **6**, 92, doi:10.1038/s41572-020-00224-3 (2020).

- 671 4 Thomas, S. J., Penfold, C. M., Waylen, A. & Ness, A. R. The changing aetiology of head
672 and neck squamous cell cancer: A tale of three cancers? *Clin Otolaryngol* **43**, 999-
673 1003, doi:10.1111/coa.13144 (2018).
- 674 5 World Health Organization (WHO). *WHO European Regional Obesity Report 2022*.
675 [Internet] [cited 2022 Jun 06],
676 <[https://apps.who.int/iris/bitstream/handle/10665/353747/9789289057738-](https://apps.who.int/iris/bitstream/handle/10665/353747/9789289057738-eng.pdf)
677 [eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/353747/9789289057738-eng.pdf)> (2022).
- 678 6 Arnold, M. *et al.* Global burden of cancer attributable to high body-mass index in
679 2012: a population-based study. *Lancet Oncol* **16**, 36-46, doi:10.1016/s1470-
680 2045(14)71123-4 (2015).
- 681 7 Tran, K. B. *et al.* The global burden of cancer attributable to risk factors, 2010-2019:
682 a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet* **400**,
683 563-591, doi:10.1016/S0140-6736(22)01438-6 (2022).
- 684 8 Davey, R. C. The obesity epidemic: too much food for thought? *British Journal of*
685 *Sports Medicine* **38**, 360-363, doi:10.1136/bjism.2003.007443 (2004).
- 686 9 Wotton, C. J., Yeates, D. G. & Goldacre, M. J. Cancer in patients admitted to hospital
687 with diabetes mellitus aged 30 years and over: record linkage studies. *Diabetologia*
688 **54**, 527-534, doi:10.1007/s00125-010-1987-2 (2011).
- 689 10 Stott-Miller, M. *et al.* History of diabetes and risk of head and neck cancer: a pooled
690 analysis from the international head and neck cancer epidemiology consortium.
691 *Cancer Epidemiol Biomarkers Prev* **21**, 294-304, doi:10.1158/1055-9965.EPI-11-0590
692 (2012).
- 693 11 Gaudet, M. M. *et al.* Anthropometry and head and neck cancer: a pooled analysis of
694 cohort data. *Int J Epidemiol* **44**, 673-681, doi:<https://dx.doi.org/10.1093/ije/dyv059>
695 (2015).

- 696 12 Jiang, H. *et al.* The effect of metabolic syndrome on head and neck cancer incidence
697 risk: a population-based prospective cohort study. *Cancer & metabolism* **9**, 25,
698 doi:<https://dx.doi.org/10.1186/s40170-021-00261-w> (2021).
- 699 13 Diaz, Y. *et al.* Body mass index and waist circumference in relation to the risk of 26
700 types of cancer: a prospective cohort study of 3.5 million adults in Spain. *BMC*
701 *Medicine* **19**, 10, doi:<http://dx.doi.org/10.1186/s12916-020-01877-3> (2021).
- 702 14 Cao, Z. *et al.* Association of obesity status and metabolic syndrome with site-specific
703 cancers: a population-based cohort study. *Brit J Cancer* **123**, 1336-1344,
704 doi:<http://dx.doi.org/10.1038/s41416-020-1012-6> (2020).
- 705 15 Gribsholt, S. B. *et al.* Hospital-diagnosed overweight and obesity related to cancer
706 risk: a 40-year Danish cohort study. *Journal of Internal Medicine* **287**, 435-447,
707 doi:<http://dx.doi.org/10.1111/joim.13013> (2020).
- 708 16 Ward, H. A. *et al.* Measured Adiposity in Relation to Head and Neck Cancer Risk in
709 the European Prospective Investigation into Cancer and Nutrition. *Cancer*
710 *epidemiology, biomarkers & prevention : a publication of the American Association*
711 *for Cancer Research, cosponsored by the American Society of Preventive Oncology*
712 **26**, 895-904, doi:<https://dx.doi.org/10.1158/1055-9965.EPI-16-0886> (2017).
- 713 17 Gong, Y., Wei, B., Yu, L. & Pan, W. Type 2 diabetes mellitus and risk of oral cancer
714 and precancerous lesions: a meta-analysis of observational studies. *Oral oncology*
715 **51**, 332-340, doi:<https://dx.doi.org/10.1016/j.oraloncology.2015.01.003> (2015).
- 716 18 Saarela, K. *et al.* Cancer incidence among Finnish people with type 2 diabetes during
717 1989-2014. *Eur J Epidemiol* **34**, 259-265, doi:[https://dx.doi.org/10.1007/s10654-018-](https://dx.doi.org/10.1007/s10654-018-0438-0)
718 [0438-0](https://dx.doi.org/10.1007/s10654-018-0438-0) (2019).
- 719 19 Kim, H.-B., Kim, G.-J., Han, K.-d. & Joo, Y.-H. Changes in metabolic syndrome status
720 and risk of laryngeal cancer: A nationwide cohort study. *PLoS ONE* **16**, e0252872-
721 e0252872, doi:<http://dx.doi.org/10.1371/journal.pone.0252872> (2021).

- 722 20 Kim, S.-Y., Han, K.-d. & Joo, Y.-H. Metabolic Syndrome and Incidence of Laryngeal
723 Cancer: A Nationwide Cohort Study. *Scientific reports* **9**, 667,
724 doi:<https://dx.doi.org/10.1038/s41598-018-37061-0> (2019).
- 725 21 Stocks, T. *et al.* Blood pressure and risk of cancer incidence and mortality in the
726 Metabolic Syndrome and Cancer Project. *Hypertension* **59**, 802-810,
727 doi:<https://dx.doi.org/10.1161/HYPERTENSIONAHA.111.189258> (2012).
- 728 22 Christakoudi, S. *et al.* Blood pressure and risk of cancer in the European Prospective
729 Investigation into Cancer and Nutrition. *Int J Cancer* **146**, 2680-2693,
730 doi:<http://dx.doi.org/10.1002/ijc.32576> (2020).
- 731 23 Seo, J.-H., Kim, Y.-D., Park, C.-S., Han, K.-d. & Joo, Y.-H. Hypertension is associated
732 with oral, laryngeal, and esophageal cancer: a nationwide population-based study.
733 *Scientific reports* **10**, 10291, doi:<https://dx.doi.org/10.1038/s41598-020-67329-3>
734 (2020).
- 735 24 Tseng, K. S., Lin, C., Lin, Y. S. & Weng, S. F. Risk of head and neck cancer in patients
736 with diabetes mellitus: a retrospective cohort study in Taiwan. *JAMA Otolaryngol*
737 *Head Neck Surg* **140**, 746-753, doi:10.1001/jamaoto.2014.1258 (2014).
- 738 25 Gatenby, R. A. & Gillies, R. J. Why do cancers have high aerobic glycolysis? *Nat Rev*
739 *Cancer* **4**, 891-899, doi:10.1038/nrc1478 (2004).
- 740 26 Warburg, O., Wind, F. & Negelein, E. The metabolism fo tumors in the body. *J Gen*
741 *Physiol* **8**, 519-530, doi:10.1085/jgp.8.6.519 (1927).
- 742 27 Scully, T., Ettela, A., LeRoith, D. & Gallagher, E. J. Obesity, Type 2 Diabetes, and
743 Cancer Risk. *Frontiers in Oncology* **10**, doi:10.3389/fonc.2020.615375 (2021).
- 744 28 Wang, W., Bai, L., Li, W. & Cui, J. The Lipid Metabolic Landscape of Cancers and New
745 Therapeutic Perspectives. *Frontiers in Oncology* **10**, doi:10.3389/fonc.2020.605154
746 (2020).

- 747 29 Covidence. *Covidence systematic review software*, Veritas Health Innovation,
748 Melbourne, Australia. [Internet] [cited 2022 July 29], <<https://www.covidence.org/>>
749 (2022).
- 750 30 Gormley, A. *et al.* Metabolic disorders and the risk of head and neck cancer: a
751 protocol for a systematic review and meta-analysis. *BMJ Open* **12**, e058392,
752 doi:10.1136/bmjopen-2021-058392 (2022).
- 753 31 Liberati, A. *et al.* The PRISMA statement for reporting systematic reviews and meta-
754 analyses of studies that evaluate healthcare interventions: explanation and
755 elaboration. *BMJ* **339**, b2700, doi:10.1136/bmj.b2700 (2009).
- 756 32 Alberti, K. G. & Zimmet, P. Z. Definition, diagnosis and classification of diabetes
757 mellitus and its complications. Part 1: diagnosis and classification of diabetes
758 mellitus provisional report of a WHO consultation. *Diabet Med* **15**, 539-553,
759 doi:10.1002/(sici)1096-9136(199807)15:7<539::Aid-dia668>3.0.Co;2-s (1998).
- 760 33 Alberti, K. G., Zimmet, P. & Shaw, J. The metabolic syndrome--a new worldwide
761 definition. *Lancet* **366**, 1059-1062, doi:10.1016/s0140-6736(05)67402-8 (2005).
- 762 34 National Cholesterol Education Program (NCEP) Expert Panel. Third Report of the
763 National Cholesterol Education Program (NCEP) Expert Panel on Detection,
764 Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment
765 Panel III) final report. *Circulation* **106**, 3143-3421 (2002).
- 766 35 World Health Organization (WHO). *Obesity and overweight* [Internet] [cited 2022
767 July 26], <[https://www.who.int/news-room/fact-sheets/detail/obesity-and-](https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight)
768 [overweight](https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight)> (2021).
- 769 36 World Health Organization (WHO). *Definition and Diagnosis of Diabetes Mellitus and*
770 *Intermediate Hyperglycaemia* [Internet] [cited 2022 July 26],
771 <[https://www.diabetes.org.uk/resources-s3/2017-](https://www.diabetes.org.uk/resources-s3/2017-09/Definition_and_diagnosis1111.pdf)
772 [09/Definition_and_diagnosis1111.pdf](https://www.diabetes.org.uk/resources-s3/2017-09/Definition_and_diagnosis1111.pdf)> (2006).

- 773 37 World Health Organization (WHO). *Use of Glycated Haemoglobin (HbA1c) in the*
774 *Diagnosis of Diabetes Mellitus [Internet] [cited 2022 July 26],*
775 [https://www.diabetes.org.uk/resources-s3/2017-](https://www.diabetes.org.uk/resources-s3/2017-09/Definition_and_diagnosis1111.pdf)
776 [09/Definition and diagnosis1111.pdf](https://www.diabetes.org.uk/resources-s3/2017-09/Definition_and_diagnosis1111.pdf)> (2011).
- 777 38 World Health Organization (WHO). *Hypertension [Internet] [cited 2022 July 26],*
778 [https://www.who.int/news-room/fact-sheets/detail/hypertension.](https://www.who.int/news-room/fact-sheets/detail/hypertension)> (2021).
- 779 39 British Medical Journal. *Hypercholesterolemia [Internet] [cited 2022 July 26],*
780 <https://bestpractice.bmj.com/topics/en-us/170>> (2019).
- 781 40 World Health Organization (WHO). *World Health Organization (WHO): International*
782 *statistical classification of diseases and related health problems (10th ed.) [Internet]*
783 *[cited 2022 July 26].* [<https://icd.who.int/browse10/2019/en#/](https://icd.who.int/browse10/2019/en#/)> (2016).
- 784 41 ROBINS-E Development Group (Higgins J, M. R., Rooney A, Taylor K, Thayer K, Silva R,
785 Lemeris C, Akl A, Arroyave W, Bateson T, Berkman N, Demers P, Forastiere F, Glenn
786 B, Hróbjartsson A, Kirrane E, LaKind J, Luben T, Lunn R, McAleenan A, McGuinness L,
787 Meerpohl J, Mehta S, Nachman R, Obbagy J, O'Connor A, Radke E, Savović J,
788 Schubauer-Berigan M, Schwingl P, Schunemann H, Shea B, Steenland K, Stewart T,
789 Straif K, Tilling K, Verbeek V, Vermeulen R, Viswanathan M, Zahm S, Sterne J). *Risk Of*
790 *Bias In Non-randomized Studies - of Exposure (ROBINS-E). Launch version, 1 June*
791 *2022.*, <https://www.riskofbias.info/welcome/robins-e-tool>]> (2022).
- 792 42 ROBINS-E Development Group, H. J., Morgan R, Rooney A, Taylor K, Thayer K, Silva R,
793 Lemeris C, Akl A, Arroyave W, Bateson T, Berkman N, Demers P, Forastiere F, Glenn
794 B, Hróbjartsson A, Kirrane E, LaKind J, Luben T, Lunn R, McAleenan A, McGuinness L,
795 Meerpohl J, Mehta S, Nachman R, Obbagy J, O'Connor A, Radke E, Savović J,
796 Schubauer-Berigan M, Schwingl P, Schunemann H, Shea B, Steenland K, Stewart T,
797 Straif K, Tilling K, Verbeek V, Vermeulen R, Viswanathan M, Zahm S, Sterne J. *Risk Of*
798 *Bias In Non-randomized Studies - of Exposure (ROBINS-E) [Internet] [cited 2022 July*
799 *29],* [https://www.riskofbias.info/welcome/robins-e-tool.](https://www.riskofbias.info/welcome/robins-e-tool)> (2022).

- 800 43 DerSimonian, R. & Laird, N. Meta-analysis in clinical trials. *Control Clin Trials* **7**, 177-
801 188, doi:10.1016/0197-2456(86)90046-2 (1986).
- 802 44 Sterne, J. A. C. *et al.* Recommendations for examining and interpreting funnel plot
803 asymmetry in meta-analyses of randomised controlled trials. *BMJ* **343**, d4002,
804 doi:10.1136/bmj.d4002 (2011).
- 805 45 Andreotti, G. *et al.* Body mass index, agricultural pesticide use, and cancer incidence
806 in the Agricultural Health Study cohort. *Cancer Causes Control* **21**, 1759-1775,
807 doi:10.1007/s10552-010-9603-9 (2010).
- 808 46 Gaudet, M. M. *et al.* Prospective studies of body mass index with head and neck
809 cancer incidence and mortality. *Cancer epidemiology, biomarkers & prevention* **21**,
810 497-503, doi:<https://dx.doi.org/10.1158/1055-9965.EPI-11-0935> (2012).
- 811 47 Hashibe, M. *et al.* Tobacco, alcohol, body mass index, physical activity, and the risk of
812 head and neck cancer in the prostate, lung, colorectal, and ovarian (PLCO) cohort.
813 *Head & neck* **35**, 914-922, doi:<https://dx.doi.org/10.1002/hed.23052> (2013).
- 814 48 Etemadi, A. *et al.* A prospective cohort study of body size and risk of head and neck
815 cancers in the NIH-AARP diet and health study. *Cancer epidemiology, biomarkers &*
816 *prevention* **23**, 2422-2429, doi:<https://dx.doi.org/10.1158/1055-9965.EPI-14-0709-T>
817 (2014).
- 818 49 Hjalgrim, H. *et al.* Cancer and diabetes--a follow-up study of two population-based
819 cohorts of diabetic patients. *J Intern Med* **241**, 471-475, doi:10.1111/j.1365-
820 2796.1997.tb00004.x (1997).
- 821 50 Wideroff, L. *et al.* Cancer incidence in a population-based cohort of patients
822 hospitalized with diabetes mellitus in Denmark. *J Natl Cancer Inst* **89**, 1360-1365,
823 doi:10.1093/jnci/89.18.1360 (1997).

- 824 51 Stocks, T. *et al.* Blood glucose and risk of incident and fatal cancer in the metabolic
825 syndrome and cancer project (me-can): analysis of six prospective cohorts. *PLoS Med*
826 **6**, e1000201, doi:10.1371/journal.pmed.1000201 (2009).
- 827 52 Tseng, C.-H. Oral cancer in Taiwan: is diabetes a risk factor? *Clinical oral*
828 *investigations* **17**, 1357-1364, doi:<https://dx.doi.org/10.1007/s00784-012-0820-3>
829 (2013).
- 830 53 Lai, G. Y., Park, Y., Hartge, P., Hollenbeck, A. R. & Freedman, N. D. The association
831 between self-reported diabetes and cancer incidence in the NIH-AARP Diet and
832 Health Study. *J Clin Endocrinol Metab* **98**, E497-502, doi:10.1210/jc.2012-3335
833 (2013).
- 834 54 Samanic, C., Chow, W. H., Gridley, G., Jarvholm, B. & Fraumeni, J. F., Jr. Relation of
835 body mass index to cancer risk in 362,552 Swedish men. *Cancer Causes Control* **17**,
836 901-909, doi:10.1007/s10552-006-0023-9 (2006).
- 837 55 Bhaskaran, K., Douglas, I., Forbes, H. & Smeeth, L. Associations between body mass
838 index and a range of cancers: A population-based study within the UK Clinical
839 Practice Research Datalink. *Eur J Epidemiol* **28**, S97,
840 doi:<http://dx.doi.org/10.1007/s10654-013-9820-0> (2013).
- 841 56 Maasland, D. H., van den Brandt, P. A., Kremer, B. & Schouten, L. J. Body mass index
842 and risk of subtypes of head-neck cancer: the Netherlands Cohort Study. *Sci Rep* **5**,
843 17744, doi:10.1038/srep17744 (2015).
- 844 57 Chodick, G. *et al.* Diabetes and risk of incident cancer: A large population-based
845 cohort study in Israel. *Cancer Causes and Control* **21**, 879-887,
846 doi:<http://dx.doi.org/10.1007/s10552-010-9515-8> (2010).
- 847 58 Atchison, E. A., Gridley, G., Carreon, J. D., Leitzmann, M. F. & McGlynn, K. A. Risk of
848 cancer in a large cohort of U.S. veterans with diabetes. *Int J Cancer* **128**, 635-643,
849 doi:<https://dx.doi.org/10.1002/ijc.25362> (2011).

- 850 59 Lo, S. F. *et al.* Modest increase in risk of specific types of cancer types in type 2
851 diabetes mellitus patients. *Int J Cancer* **132**, 182-188,
852 doi:<http://dx.doi.org/10.1002/ijc.27597> (2013).
- 853 60 Walker, J. J. *et al.* Type 2 diabetes, socioeconomic status and risk of cancer in
854 Scotland 2001-2007. *Diabetologia* **56**, 1712-1715,
855 doi:<http://dx.doi.org/10.1007/s00125-013-2937-6> (2013).
- 856 61 Nakamura, K. *et al.* Diabetes mellitus and risk of cancer in Takayama: a population-
857 based prospective cohort study in Japan. *Cancer Sci* **104**, 1362-1367,
858 doi:10.1111/cas.12235 (2013).
- 859 62 Lin, C. C. *et al.* Cancer risks among patients with type 2 diabetes: A 10-year follow-up
860 study of a nationwide population-based cohort in Taiwan. *BMC Cancer* **14**, 381,
861 doi:<http://dx.doi.org/10.1186/1471-2407-14-381> (2014).
- 862 63 He, X., Shi, L. & Wu, J. Retrospective database analysis of cancer risk in patients with
863 type 2 diabetes mellitus in China. *Current Medical Research and Opinion* **34**, 1089-
864 1098, doi:<http://dx.doi.org/10.1080/03007995.2017.1421527> (2018).
- 865 64 Qi, J. *et al.* Cancer risk among patients with type 2 diabetes: A real-world study in
866 Shanghai, China. *J Diabetes* **11**, 878-883, doi:10.1111/1753-0407.12926 (2019).
- 867 65 Chyou, P. H., Nomura, A. M., Stemmermann, G. N. & Kato, I. Prospective study of
868 serum cholesterol and site-specific cancers. *Journal of clinical epidemiology* **45**, 287-
869 292 (1992).
- 870 66 Gaudet, M. M. *et al.* Anthropometry and head and neck cancer: a pooled analysis of
871 cohort data. *Int J Epidemiol* **44**, 673-681, doi:10.1093/ije/dyv059 (2015).
- 872 67 Chen, Y. *et al.* Body mass index and the risk of head and neck cancer in the Chinese
873 population. *Cancer Epidemiol* **60**, 208-215, doi:10.1016/j.canep.2019.04.008 (2019).

- 874 68 Holmberg, M. J. & Andersen, L. W. Collider Bias. *JAMA* **327**, 1282-1283,
875 doi:10.1001/jama.2022.1820 (2022).
- 876 69 Dare, S., Mackay, D. F. & Pell, J. P. Relationship between smoking and obesity: a
877 cross-sectional study of 499,504 middle-aged adults in the UK general population.
878 *PLoS One* **10**, e0123579, doi:10.1371/journal.pone.0123579 (2015).
- 879 70 Jager-Wittenaar, H. *et al.* Critical weight loss in head and neck cancer--prevalence
880 and risk factors at diagnosis: an explorative study. *Support Care Cancer* **15**, 1045-
881 1050, doi:10.1007/s00520-006-0212-9 (2007).
- 882 71 Strulov Shachar, S. & Williams, G. R. The Obesity Paradox in Cancer-Moving Beyond
883 BMI. *Cancer Epidemiol Biomarkers Prev* **26**, 13-16, doi:10.1158/1055-9965.Epi-16-
884 0439 (2017).
- 885 72 Saeedi, P. *et al.* Global and regional diabetes prevalence estimates for 2019 and
886 projections for 2030 and 2045: Results from the International Diabetes Federation
887 Diabetes Atlas, 9(th) edition. *Diabetes Res Clin Pract* **157**, 107843,
888 doi:10.1016/j.diabres.2019.107843 (2019).
- 889 73 Blüher, M. Obesity: global epidemiology and pathogenesis. *Nature Reviews*
890 *Endocrinology* **15**, 288-298, doi:10.1038/s41574-019-0176-8 (2019).
891

Supplementary information

Supplementary Appendix 1 Systematic review protocol

Supplementary Appendix 2 PRISMA checklist

Supplementary Table 1 Search strategy

1

exp "HEAD AND NECK NEOPLASMS"/

2

("head and neck cancer" or "oral cancer").ti,ab.

3

((lip or lips or mouth or gums or palatal or palate or gingiva* or buccal or cheek* or tongue or lingual or glosso* or laryn* or "vocal chord*" or "vocal cord*" or "vocal fold*" or subglottic or supraglottic or hypopharynx* or hypo-pharynx* or epiglottis or arytenoids or aryepiglottic or throat or oropharynx* or oropharynx* or tonsil* or pharynx* or otolarynx* or jaw or mandib* or maxill*) adj3 (cancer* or carcinoma* or neoplasm* or tumour* or tumor* or squamous or lymphoma* or HPV or "human papillomavirus").ti,ab.

4

1 or 2 or 3

5

exp DYSLIPIDEMIAS/

6

(dyslipidaemia or dyslipidemia or lipolysis or hypercholesterolemia or hypercholesterolaemia or "low density lipoprotein" or "apolipoprotein" or cholesterol or LDL or triglycerides or statin* or ezetimibe or "HMG-CoA" or "reductase inhibitor*" or "HMGCR" or "hydroxymethylglutaryl coa reductases" or "NPC1L1" or "PCSK9" or "CETP" or "LDLR" or atorvastatin or fluvastatin or lovastatin or pitavastatin or pravastatin or rosuvastatin or simvastatin or (lipid* adj2 (metaboli* or medicat* or drug* or lower* or reduc* or decreas*))).ti,ab.

7

5 or 6

8

exp DIABETES MELLITUS/

9

(Diabet* or insulin or "insulin resistance" or hyperglycaemia or hypoglycaemia or hyperglycemia or hypoglycemia or hypertension or metformin or glucagon or "hypoglycaemic agent*" or HbA1 or HbA1c or (glucose adj2 (impair* or tolerance or intolerance)) or IGT or glycogenolysis or gluconeogenesis or GDF?15 or gliflozins or SGLT2 or sulphonylurea* or meglitinide* or thiazolidinediones or "DPP-4 inhibitor*" or "GLP-1 receptor agonist").ti,ab.

10

8 or 9

11

exp METABOLIC SYNDROME/

12

(metabolic syndrome or "dyregulated metaboli*" or obesity or obes* or "abdominal obes*" or (fat or fatty or fats) or "body weight" or adipos* or (weight adj2 gain*) or overeate* or bariatric or (over adj2 eat) or "body mass index*" or BMI).ti,ab.

13

11 or 12

14

7 or 10 or 13

15

4 and 14

16

exp RISK/

17

(risk* or inciden* or prevalen*).ti,ab.

18

16 or 17

19

15 and 18

Supplementary Table 2 Modified search strategy

1
HEAD AND NECK CANCER
2
AND
3
CHOLESTEROL
4
OR
5
DIABETES
6
OR
7
METABOLIC SYNDROME
8
OR
9
OBESITY

Supplementary Table 3 Subgroup analyses for the association of metabolic disorders and risk of head and neck cancer

Characteristic	Subgroup	Effect size (RR, 95% CI)	P heterogeneity	I ² (%)	P difference between groups
Obesity					
Age	<50	0.95 (0.87 - 1.04)	0.567	0	0.396
	>50	1.05 (0.85 - 1.29)	0.119	43.0	
Geographic location	Asian	NA	NA	NA	0.007
	European	0.97 (0.90 - 1.04)	0.613	0	
	USA	1.40 (1.08 - 1.81)	NA (single study)	NA	
Year of publication	After 2010	0.99 (0.90 - 1.08)	0.183	22.9	0.855
	Before 2010	0.94 (0.57 - 1.56)	NA (single study)	NA	
Methods of exposure assessment	MR	0.94 (0.86 - 1.04)	0.543	0	0.011
	SR	0.63 (0.38 - 1.06)	0.802	0	
	Measured at baseline	1.02 (0.91 - 1.15)	0.586	0	
	Combination	1.40 (1.08 - 1.81)	NA (single study)	NA	
Adjustment for age, sex, smoking and alcohol as confounders	Yes	1.00 (0.89 - 1.12)	0.433	0.1	0.816
	No	0.98 (0.87 - 1.11)	0.088	45.6	
Length of follow-up	<10 years	1.00 (0.91 - 1.10)	0.125	38.3	0.697
	≥10 years	0.93 (0.75 - 1.16)	0.357	9.3	
Number of cancer cases	<50	0.85 (0.67 - 1.06)	0.518	0	0.323
	≥50	1.00 (0.91 - 1.10)	0.125	38.3	
Type 2 diabetes mellitus					
Age	<50	1.09 (1.01 - 1.17)	<0.0001	74.7	0.937
	>50	1.09 (0.96 - 1.25)	<0.0001	94.2	
Geographic location	Asian	1.23 (1.13 - 1.33)	<0.0001	78.6	<0.0001
	European	1.00 (0.90 - 1.12)	0.001	68.1	

	USA	0.81 (0.72 - 0.90)	0.002	89.1	
Year of publication	After 2010	1.10 (1.00 - 1.20)	<0.0001	93	NA
	Before 2010	NA	NA	NA	
Methods of exposure assessment	MR	1.05 (0.93 - 1.18)	<0.0001	93.3	0.082
	SR	NA	NA	NA	
	Measured at baseline	1.12 (1.06 - 1.19)	NA (single study)	NA	
	Combination	1.19 (1.13 - 1.25)	0.343	11.3	
Adjustment for age, sex, smoking and alcohol as confounders	Yes	1.15 (1.10 - 1.20)	0.524	0	0.281
	No	1.07 (0.96 - 1.20)	<0.0001	93.7	
Length of follow-up	<10 years	1.12 (1.04 - 1.21)	0.003	61.3	0.838
	≥10 years	1.11 (0.97 - 1.26)	<0.0001	95	
Number of cancer cases	<50	1.08 (0.84 - 1.38)	0.003	65.5	0.815
	≥50	1.11 (1.01 - 1.23)	<0.0001	95.3	
Hypertension					
Age	<50	1.16 (1.08 - 1.25)	0.129	47.1	0.983
	>50	1.16 (1.08 - 1.24)	0.155	37.7	
Geographic location	Asian	1.14 (1.09 - 1.20)	0.205	34.5	0.597
	European	1.18 (1.07 - 1.30)	0.156	37.6	
	USA	NA	NA	NA	
Year of publication	After 2010	1.16 (1.11 - 1.21)	0.133	34.3	NA
	Before 2010	NA	NA	NA	
Methods of exposure assessment	MR	NA	NA	NA	NA
	SR	NA	NA	NA	
	Measured at baseline	1.16 (1.11 - 1.21)	0.133	34.4	
	Combination	NA	NA	NA	
Adjustment for age, sex, smoking and alcohol as confounders	Yes	1.15 (1.10 - 1.19)	0.287	19.1	0.619
	No	1.19 (0.96 - 1.48)	0.071	69.3	
Length of follow-up	<10 years	1.23 (1.13 - 1.33)	0.379	4.9	0.121

	≥10 years	1.14 (1.09 - 1.19)	0.175	36.9	
Number of cancer cases	<50	NA)	NA	NA	NA
	≥50	1.16 (1.11 - 1.21)	0.113	34.3	
Dyslipidaemia					
Age	<50	1.12 (1.08 - 1.16)	0.191	36.9	0.047
	>50	0.94 (0.80 - 1.11)	0.251	26.7	
Geographic location	Asian	1.12 (1.08 - 1.16)	0.191	36.9	0.006
	European	0.97 (0.87 - 1.10)	0.619	0	
	USA	0.45 (0.21 - 0.98)	0.692	0	
Year of publication	After 2010	1.10 (1.06 - 1.15)	0.063	52.3	0.024
	Before 2010	0.45 (0.21 - 0.98)	0.692	0	
Methods of exposure assessment	MR	NA	NA	NA	NA
	SR	NA	NA	NA	
	Measured at baseline	1.09 (1.04 - 1.15)	0.026	56	
	Combination	NA	NA	NA	
Adjustment for age, sex, smoking and alcohol as confounders	Yes	1.10 (1.06 - 1.15)	0.063	52.3	0.024
	No	0.45 (0.21 - 0.98)	0.692	0	
Length of follow-up	<10 years	1.10 (1.06 - 1.15)	0.063	52.3	0.024
	≥10 years	0.45 (0.21 - 0.98)	0.692	0	
Number of cancer cases	<50	0.45 (0.21 - 0.98)	0.692	0	0.024
	≥50	1.10 (1.06 - 1.15)	0.063	52.3	

Supplementary Figures 1 – 4 Risk of bias assessments for each metabolic trait using the ROBINS-E tool

Supplementary Figure 1 Obesity

		Risk of bias domains							
		D1	D2	D3	D4	D5	D6	D7	Overall
Study	Bhaskaran, 2014	⊗	⊕	⊕	⊕	⊖	⊕	⊕	⊗
	Cao, 2020	⊕	⊕	⊕	⊕	⊕	⊕	⊕	⊕
	Gaudet, 2015	⊖	⊖	⊕	⊕	⊖	⊕	⊕	⊖
	Gribsholt, 2020	⊗	⊕	⊕	⊕	⊗	⊕	⊕	⊗
	Jiang, 2021	⊕	⊕	⊕	⊕	⊕	⊕	⊕	⊕
	Maasland, 2015	⊖	⊖	⊕	⊕	⊗	⊕	⊕	⊗
	Samanic, 2006	⊗	⊕	⊕	⊕	⊖	⊕	⊕	⊗
	Ward, 2017	⊗	⊖	⊕	⊕	⊖	⊕	⊕	⊗

Domains:
D1: Bias due to confounding.
D2: Bias arising from measurement of the exposure.
D3: Bias in selection of participants into the study (or into the analysis).
D4: Bias due to post-exposure interventions.
D5: Bias due to missing data.
D6: Bias arising from measurement of the outcome.
D7: Bias in selection of the reported result.

Judgement
⊗ High
⊖ Some concerns
⊕ Low

Supplementary Figure 2 Type 2 Diabetes

Study	Risk of bias domains							Overall
	D1	D2	D3	D4	D5	D6	D7	
Atchison, 2011	⊗	+	+	+	+	+	+	⊗
Chodick, 2010	⊗	+	+	+	⊗	+	+	⊗
Gong, 2015	⊗	+	+	+	⊗	+	+	⊗
He, 2018	⊗	+	+	+	⊗	+	+	⊗
Jiang, 2021	+	+	+	+	+	+	+	+
Kim, 2019	-	+	+	+	⊗	+	+	⊗
Kim, 2021	-	+	+	+	⊗	+	+	⊗
Lin, 2014	⊗	+	+	+	⊗	+	+	⊗
Lo, 2013	⊗	+	+	+	+	+	+	⊗
Nakamura, 2013	⊗	+	+	+	⊗	+	+	⊗
Qi, 2019	⊗	+	+	+	⊗	+	+	⊗
Saarela, 2019	⊗	+	+	+	+	+	+	⊗
Seo, 2020	-	+	+	+	⊗	+	+	⊗
Tseng, 2014	⊗	+	+	+	⊗	+	+	⊗
Walker, 2013	⊗	+	+	+	⊗	+	+	⊗

Domains:
D1: Bias due to confounding.
D2: Bias arising from measurement of the exposure.
D3: Bias in selection of participants into the study (or into the analysis).
D4: Bias due to post-exposure interventions.
D5: Bias due to missing data.
D6: Bias arising from measurement of the outcome.
D7: Bias in selection of the reported result.

Judgement
⊗ Very high
⊗ High
- Some concerns
+ Low

Supplementary Figure 3 Hypertension

		Risk of bias domains							
		D1	D2	D3	D4	D5	D6	D7	Overall
Study	Christakoudi, 2020								
	Jiang, 2021								
	Kim, 2019								
	Kim, 2021								
	Seo, 2020								
	Stocks, 2012								

Domains:
D1: Bias due to confounding.
D2: Bias arising from measurement of the exposure.
D3: Bias in selection of participants into the study (or into the analysis).
D4: Bias due to post-exposure interventions.
D5: Bias due to missing data.
D6: Bias arising from measurement of the outcome.
D7: Bias in selection of the reported result.

Judgement
 High
 Some concerns
 Low

Supplementary Figure 4 Dyslipidaemia

		Risk of bias domains							
		D1	D2	D3	D4	D5	D6	D7	Overall
Study	Chyou, 1992								
	Jiang, 2021								
	Kim, 2019								
	Kim, 2021								

Domains:

- D1: Bias due to confounding.
- D2: Bias arising from measurement of the exposure.
- D3: Bias in selection of participants into the study (or into the analysis).
- D4: Bias due to post-exposure interventions.
- D5: Bias due to missing data.
- D6: Bias arising from measurement of the outcome.
- D7: Bias in selection of the reported result.

Judgement

- High
- Some concerns
- Low